NYSE American - Delayed Quote USD

AIM ImmunoTech Inc. (AIM)

Compare
0.2150
-0.0020
(-0.92%)
At close: January 10 at 4:00:00 PM EST
0.2068
-0.01
(-3.81%)
After hours: 7:54:13 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
190.0000
--
141.0000
135.0000
163.0000
Cost of Revenue
36.0000
--
--
850.0000
806.0000
Gross Profit
154.0000
--
141.0000
-715.0000
-643.0000
Operating Expense
28,075.0000
--
20,064.0000
16,344.0000
14,374.0000
Operating Income
-27,921.0000
--
-19,923.0000
-17,059.0000
-15,017.0000
Net Non Operating Interest Income Expense
3,184.0000
--
629.0000
-67.0000
-672.0000
Other Income Expense
808.0000
--
-151.0000
-2,001.0000
1,289.0000
Pretax Income
-23,929.0000
--
-19,445.0000
-19,127.0000
-14,400.0000
Net Income Common Stockholders
-23,929.0000
--
-19,445.0000
-19,127.0000
-14,400.0000
Diluted NI Available to Com Stockholders
-23,929.0000
--
-19,445.0000
-19,127.0000
-14,400.0000
Basic EPS
-0.47
-0.60
-0.40
-0.40
-0.45
Diluted EPS
-0.47
-0.60
-0.40
-0.40
-0.45
Basic Average Shares
52,236.1530
48,585.4040
48,047.2880
47,339.9750
31,842.7990
Diluted Average Shares
52,236.1530
48,585.4040
48,047.2880
47,339.9750
31,842.7990
Total Operating Income as Reported
-27,921.0000
--
-19,923.0000
-18,838.0000
-15,152.0000
Total Expenses
28,111.0000
--
20,064.0000
17,194.0000
15,180.0000
Net Income from Continuing & Discontinued Operation
-23,929.0000
--
-19,445.0000
-19,127.0000
-14,400.0000
Normalized Income
-23,970.0000
--
-17,804.0000
-14,807.0000
-14,503.0000
Interest Income
3,637.0000
--
629.0000
--
219.0000
Interest Expense
--
--
--
67.0000
672.0000
Net Interest Income
3,184.0000
--
629.0000
-67.0000
-672.0000
EBIT
-26,430.0000
--
-19,923.0000
-19,060.0000
-13,728.0000
EBITDA
-26,190.0000
--
-19,667.0000
-18,285.0000
-12,995.0000
Reconciled Cost of Revenue
36.0000
--
--
850.0000
806.0000
Reconciled Depreciation
240.0000
--
256.0000
775.0000
733.0000
Net Income from Continuing Operation Net Minority Interest
-23,929.0000
--
-19,445.0000
-19,127.0000
-14,400.0000
Total Unusual Items Excluding Goodwill
41.0000
--
-1,641.0000
-4,320.0000
103.0000
Total Unusual Items
41.0000
--
-1,641.0000
-4,320.0000
103.0000
Normalized EBITDA
-26,231.0000
--
-18,026.0000
-13,965.0000
-13,098.0000
12/31/2020 - 7/12/1996

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

INAB IN8bio, Inc.
0.3233
+3.42%
 
NNVC NanoViricides, Inc.
1.3500
-2.88%
 
SYRS Syros Pharmaceuticals, Inc.
0.2250
+7.14%
 
COCP Cocrystal Pharma, Inc.
2.2100
-7.14%
 
IGC IGC Pharma, Inc.
0.3450
+4.12%
 
LYRA Lyra Therapeutics, Inc.
0.1955
-2.59%
 
VIRX Viracta Therapeutics, Inc.
0.1860
-0.91%
 
APTO Aptose Biosciences Inc.
0.2200
+3.19%
 
IPA ImmunoPrecise Antibodies Ltd.
0.5285
-2.85%
 
TSBX Turnstone Biologics Corp.
0.4802
-11.07%